Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1351
Shown on this page
12
Current sort
Recently updated
Location scope
New Haven, CT
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within New Haven, Connecticut. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 373–384 of 1,351 matching trials in New Haven, CT.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT06003231
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
Interventions
disitamab vedotin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
75
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Neuro-immune Interactome in Parkinson's Disease

NCT07026929
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
40 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Recruiting Not applicable Interventional

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

NCT07291180
View directory record Official record
Conditions
Appendiceal Cancer, Colorectal Adenocarcinoma, Peritoneal Metastases
Interventions
Mass-based response testing (MRT)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 81 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Recruiting Phase 3 Interventional

Emergency Department-Initiated Medications for Alcohol Use Disorder

NCT05827159
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview, Gabapentin Pill
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Completed Phase 2 Interventional Results available

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

NCT05676294
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Recruiting Not applicable Interventional

Promoting Palliative Care for People With Heart Failure

NCT06933875
View directory record Official record
Conditions
Heart Failure, Palliative Care
Interventions
Clinical Decision Support Tool
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Recruiting No phase listed Observational

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

NCT05907629
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerotic Stenosis (ICAS)
Interventions
MRI
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
28
States / cities
Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Completed Not applicable Interventional

Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients

NCT04217551
View directory record Official record
Conditions
Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
Interventions
Therapeutic Hypothermia
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
76
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Recruiting Phase 3 Interventional

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
374
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Active, not recruiting No phase listed Observational

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

NCT05388708
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Interventions
ECMO support, PROSpect protocolized therapies
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
14 Days to 20 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 8, 2026, 6:48 AM EST
Completed Not applicable Interventional Results available

Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)

NCT04180020
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
ID/LAB, TAU
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • Hershey, Pennsylvania • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 8, 2026, 6:48 AM EST